Drug Screening Market Size To Reach $19.09 Billion By 2033

Drug Screening Market Growth & Trends

The global drug screening market size is expected to reach USD 19.09 billion by 2033, registering a CAGR of 7.12% from 2026 to 2033, according to a new report by Grand View Research, Inc. The market is driven by increasing workplace safety concerns, regulatory compliance, and the requirement for accurate detection of substance abuse, aided by technological advancements in testing methods.

The increase in number of adults in contact with drug and alcohol services in England has increased from 275,896 in 2020 - 2021­ to 289,215 in 2021 - 2022, representing a 4.8% rise, which signifies a growing prevalence of substance abuse in the country. The rising prevalence of substance abuse further propels the need for effective prevention and treatment strategies, including the expansion of access to evidence-based treatment options and public health campaigns to raise awareness about the risks of drug and alcohol misuse.

Furthermore, the incidence of illegal substance uses amongst Americans aged 12 and older in 2020 was around 37.31 million, and shows a 3.8% year-over-year increase over the years; this rising prevalence serves as a significant driver for the market. This increase highlights the urgent need for comprehensive drug screening programs in workplaces, schools, and healthcare settings to ensure safety, compliance with regulations, and provision of appropriate care and support for individuals struggling with substance abuse.

Furthermore, initiatives by market players such as new product launches, mergers, acquisitions, and others contribute to market growth. For instance, in February 2024, Mobile Health,  the leading drug testing provider in NYC, launched rapid drug testing for employers, ensuring results in an hour or less. With a focus on urine-based testing for accuracy and versatility, this innovation advances the hiring procedure, revolutionizing talent acquisition in NYC. In addition, in December 2023, the FDA's approval of the AvertD test, which assesses an individual's risk of developing opioid use disorder through genetic markers, marks a significant innovation in the fight against the opioid crisis. This test, developed by AutoGenomics, Inc., is designed to be used before a patient is first exposed to oral opioid pain medications, particularly in patients scheduled for surgical procedures. The test is intended to help patients and healthcare providers make informed decisions about opioid use, potentially reducing the risk of addiction and misuse.

 Request a free sample copy or view report summary: Drug Screenin Market Report

Drug Screening Market Report Highlights

• Consumables held the largest revenue share of 34.82% in 2025, attributed to their essential role in rapid, accurate, and on-site testing. Furthermore, frequent product launches and the need for efficient substance detection across workplaces and healthcare settings also fuel this segment’s growth

• Services and others are expected to grow at a CAGR of 7.16% over the forecast period, owing to the increasing need for specialized drug screening services, including laboratory analysis and support for compliance with regulatory standards.

• Urine samples dominated the market with the largest revenue share of 41.52% in 2025, primarily driven by their noninvasive, simple, and convenient collection process, which makes them suitable for both workplace and clinical settings.

• Oral fluid samples are expected to grow at a significant CAGR over the forecast period, driven by their ease of collection, minimal privacy concerns, and lower risk of sample adulteration.

• North America dominated the global drug screening market with the largest revenue share in 2025, driven by rising substance abuse rates, stringent workplace safety regulations, and increasing government initiatives aimed at controlling drug-related issues

Drug Screening Market Report Segmentation

Grand View Research has segmented the global drug screening market based on product, sample, end use, and region:

Drug Screening Product Outlook (Revenue, USD Billion, 2021 - 2033)

• Instruments

  • Immunoassays Analyzers

  • Chromatography Instruments

  • Breath Analyzer

    • Fuel Cell Breath Analyzer

    • Semi-Conductor Breath Analyzer

    • Others Breath Analyzer

• Rapid Testing Devices

  • Urine Testing Devices

    • Drug Testing Cups

    • Dip Cards

    • Drug Testing Cassettes

  • Oral Fluid Testing Devices

• Consumables

  • Assay Kits

  • Sample Collection Devices

  • Calibrators & Controls

  • Other Consumables

• Services and Others

Drug Screening Sample Outlook (Revenue, USD Billion, 2021 - 2033)

• Urine Samples

• Breath Samples

• Oral Fluid Samples

• Hair Samples

• Other Samples

Drug Screening End Use Outlook (Revenue, USD Billion, 2021 - 2033)

• Hospitals

• Criminal Justice & Law Enforcement Agencies

• Workplaces

• Drug Treatment Centers

• Individual Users

• Pain Management Centers

• Schools & Colleges

• Others

Drug Screening Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • Kuwait

  • UAE

List Of Key Players Drug Screening Market

• Abbott

• Quest Diagnostics Incorporated

• F. Hoffmann-La Roche Ltd

• Thermo Fisher Scientific Inc.

• Siemens Healthcare AG

• Laboratory Corporation of America Holdings

• Alfa Scientific Designs, Inc.

• OraSure Technologies, Inc.

• Omega Laboratories, Inc.

• Drägerwerk AG & Co. KGaA

• Bio-Rad Laboratories, Inc.